Insulet Total Liabilities 2010-2024 | PODD
Insulet total liabilities from 2010 to 2024. Total liabilities can be defined as the total value of all possible claims against the corporation.
- Insulet total liabilities for the quarter ending December 31, 2024 were $1.876B, a 1.11% increase year-over-year.
- Insulet total liabilities for 2024 were $1.876B, a 1.11% increase from 2023.
- Insulet total liabilities for 2023 were $1.856B, a 4.55% increase from 2022.
- Insulet total liabilities for 2022 were $1.775B, a 18.91% increase from 2021.
| Insulet Annual Total Liabilities (Millions of US $) |
|
|---|---|
| 2024 | $1,876 |
| 2023 | $1,856 |
| 2022 | $1,775 |
| 2021 | $1,493 |
| 2020 | $1,269 |
| 2019 | $1,067 |
| 2018 | $717 |
| 2017 | $658 |
| 2016 | $393 |
| 2015 | $241 |
| 2014 | $213 |
| 2013 | $163 |
| 2012 | $154 |
| 2011 | $139 |
| 2010 | $90 |
| 2009 | $111 |
| Insulet Quarterly Total Liabilities (Millions of US $) |
|
|---|---|
| 2024-12-31 | $1,876 |
| 2024-09-30 | $1,907 |
| 2024-06-30 | $1,883 |
| 2024-03-31 | $1,833 |
| 2023-12-31 | $1,856 |
| 2023-09-30 | $1,860 |
| 2023-06-30 | $1,832 |
| 2023-03-31 | $1,786 |
| 2022-12-31 | $1,775 |
| 2022-09-30 | $1,738 |
| 2022-06-30 | $1,691 |
| 2022-03-31 | $1,623 |
| 2021-12-31 | $1,493 |
| 2021-09-30 | $1,501 |
| 2021-06-30 | $1,465 |
| 2021-03-31 | $1,255 |
| 2020-12-31 | $1,269 |
| 2020-09-30 | $1,116 |
| 2020-06-30 | $1,063 |
| 2020-03-31 | $1,049 |
| 2019-12-31 | $1,067 |
| 2019-09-30 | $1,118 |
| 2019-06-30 | $728 |
| 2019-03-31 | $729 |
| 2018-12-31 | $717 |
| 2018-09-30 | $688 |
| 2018-06-30 | $660 |
| 2018-03-31 | $659 |
| 2017-12-31 | $658 |
| 2017-09-30 | $426 |
| 2017-06-30 | $395 |
| 2017-03-31 | $381 |
| 2016-12-31 | $393 |
| 2016-09-30 | $388 |
| 2016-06-30 | $236 |
| 2016-03-31 | $228 |
| 2015-12-31 | $241 |
| 2015-09-30 | $238 |
| 2015-06-30 | $230 |
| 2015-03-31 | $225 |
| 2014-12-31 | $213 |
| 2014-09-30 | $221 |
| 2014-06-30 | $247 |
| 2014-03-31 | $166 |
| 2013-12-31 | $163 |
| 2013-09-30 | $168 |
| 2013-06-30 | $148 |
| 2013-03-31 | $151 |
| 2012-12-31 | $154 |
| 2012-09-30 | $153 |
| 2012-06-30 | $145 |
| 2012-03-31 | $145 |
| 2011-12-31 | $139 |
| 2011-09-30 | $132 |
| 2011-06-30 | $132 |
| 2011-03-31 | $89 |
| 2010-12-31 | $90 |
| 2010-09-30 | $116 |
| 2010-06-30 | $118 |
| 2010-03-31 | $118 |
| 2009-12-31 | $111 |
| 2009-09-30 | $117 |
| 2009-06-30 | $103 |
| 2009-03-31 | $104 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | MED PRODUCTS | $18.084B | $2.072B |
| Insulet Corporation is a leading developer, manufacturer and marketer of the Omnipod Insulin Management System. The system is equipped with a self-adhesive, small and lightweight disposable tubeless Omnipod device along with the wireless and handheld Personal Diabetes Manager (PDM). The Omnipod System is an innovative, discreet and easy-to-use continuous insulin delivery system for people with insulin-dependent diabetes. The Omnipod System consists of Omnipod Insulin Management System ('Omnipod') and the Omnipod DASH Insulin Management System - Insulet's next generation digital mobile Omnipod platform. Insulet has tied up with pharmaceutical and biotechnological companies using customized form of the Omnipod System to deliver a drug at a certain administered volume and over a specified period of time. Insulet has partnered with pharmaceutical and biotechnology companies to tailor the Omnipod System technology platform for the delivery of subcutaneous drugs across other therapeutic areas. | |||